Plasma and cerebrospinal fluid biomarkers predict cerebral injury in HIV-infected individuals on stable combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 1, 2015, Pages 29-35

  Anderson, Albert M ^a   Harezlak, Jaroslaw ^b   Bharti, Ajay ^c   Mi, Deming ^b   Taylor, Michael J ^c   Daar, Eric S ^d   Schifitto, Giovanni ^e   Zhong, Jianhui ^e   Alger, Jeffry R ^d   Brown, Mark S ^f   Singer, Elyse J ^d   Campbell, Thomas B ^f   McMahon, Deborah D ^g   Buchthal, Steven ^h   Cohen, Ronald ⁱ   Yiannoutsos, Constantin ^b   Letendre, Scott L ^c   Navia, Bradford A ^j  

^a EMORY UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h UNIVERSITY OF HAWAII   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AIDS; cerebrospinal fluid; HIV; HIV associated neurocognitive disorder

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CD14 ANTIGEN; CHOLINE; CREATINE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMIC ACID; GLUTAMINE; INDINAVIR; INOSITOL; LAMIVUDINE; LOPINAVIR; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLASPARTIC ACID; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; AIDS DEMENTIA COMPLEX SCALE; ANTIVIRAL THERAPY; ARTICLE; BASAL GANGLION; BLOOD ANALYSIS; BRAIN INJURY; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; FUNCTIONAL DISEASE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; WHITE MATTER; BLOOD; BRAIN; CEREBROSPINAL FLUID; CHEMISTRY; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PATHOLOGY; PLASMA;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BRAIN; CEREBROSPINAL FLUID; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLASMA;

EID: 84928436722     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000532     Document Type: Article

References (46)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
2. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008;16:94-98.
3. Dore GJ, McDonald A, Li Y, et al; National HIVSC. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539-1545.
4. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21:1915-1921.
5. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21:706-713.
6. Cohen RA, Harezlak J, Gongvatana A, et al. Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol. 2010;16:435-444.
7. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25:625-633.
8. Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics. 2007;4:330-345.
9. Sacktor N, Skolasky RL, Ernst T, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging. 2005;21:325-333.
10. Tracey I, Lane J, Chang I, et al. 1H magnetic resonance spectroscopy reveals neuronal injury in a simian immunodeficiency virus macaque model. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:21-27.
11. Yiannoutsos CT, Ernst T, Chang L, et al. Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage. 2004;23:928-935.
12. Cotter R, Williams C, Ryan L, et al. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. J Neuroviro. 2002;8:585-598.
13. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr. 2012;60:234-243.
14. Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831-835.
15. Kolb SA, Sporer B, Lahrtz F, et al. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferongamma inducible protein 10. J Neuroimmunol. 1999;93:172-181.
16. Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis. 1999;180:310-319.
17. Marcotte TD, Deutsch R, Michael BD, et al. A concise panel of biomarkers Identifies neurocognitive functioning changes in HIVinfected individuals. J Neuroimmune Pharmacol. 2013;8(5):1123-1135.
18. Chang L, Ernst T, St Hillaire C, et al. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther. 2004;9:431-440.
19. Gongvatana A, Harezlak J, Buchthal S, et al. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol. 2013;19:209-218.
20. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39:633-645.
21. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LC Model. NMR Biomed. 2001;14:260-264.
22. Lee PL, Yiannoutsos CT, Ernst T, et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging. 2003;17:625-633.
23. Price RW, Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239:586-592.
24. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm. 1994;22:431-445.
25. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-2096.
26. Hua X, Boyle CP, Harezlak J, et al. Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin. 2013;3:132-142.
27. Zhu T, Zhong J, Hu R, et al. Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study. J Neurovirol. 2013;19:10-23.
28. Cohen RA, Harezlak J, Schifitto G, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 2010;16:25-32.
29. Cohen RA, de la Monte S, Gongvatana A, et al. Plasma cytokine concentrations associated with HIV/hepatitis C coinfection are related to attention, executive and psychomotor functioning. J Neuroimmunol. 2011;233:204-210.
30. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5:69-81.
31. Cysique LA, Moffat K, Moore DM, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One. 2013;8:e61738.
32. Letendre SL, Zheng JC, Kaul M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63-69.
33. Sanders VJ, Pittman CA, White MG, et al. Chemokines and receptors in HIV encephalitis. AIDS. 1998;12:1021-1026.
34. Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol. 2004;157:185-192.
35. Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol. 1994;98:369-374.
36. Thomas JB, Brier MR, Snyder AZ, et al. Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology. 2013;80:1186-1193.
37. Monteiro de Almeida S, Letendre S, Zimmerman J, et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol. 2005;169: 144-152.
38. Sui Y, Potula R, Dhillon N, et al. Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am J Pathol. 2004;164:1557-1566.
39. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917-924.
40. Sheridan GK, Murphy KJ. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol. 2013;3:130181.
41. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469.
42. Reiner AP, Lange EM, Jenny NS, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33:158-164.
43. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292-1299.
44. Anderson AM, Waldrop-Valverde D, Lennox JL, Patel N, et al. CSF interferon alpha levels Inversely correlate with processing and motor speed in HIV-infected subjects with cognitive complaints with and without HAND. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; 2013; Poster Abstract 437.
45. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS. 1992;6:461-465.
46. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.